The nurse is teaching a client on a new medication for treatment of DMII. The nurse teaches to monitor the blood glucose after taking the drug. since it stimulates the release of insulin from the pancreas. Which drug is this?

Rationale: A. Glucagon: Glucagon is a hormone that raises blood glucose by stimulating glycogenolysis and gluconeogenesis in the liver. It is used to treat severe hypoglycemia, not to lower blood glucose in diabetes, so it does not stimulate insulin release from the pancreas. B. Glipizide: Glipizide is a sulfonylurea that stimulates pancreatic beta cells to release insulin, lowering blood glucose levels. Clients taking glipizide need to monitor for hypoglycemia, especially after meals, because the drug increases endogenous insulin regardless of current glucose levels. C. Glargine: Glargine is a long-acting insulin analog that provides basal insulin replacement. It does not stimulate endogenous insulin release but instead supplies exogenous insulin for blood glucose control. Blood glucose monitoring is still required, but the mechanism differs from insulin secretagogues. D. Metformin: Metformin is a biguanide that lowers blood glucose primarily by decreasing hepatic gluconeogenesis and improving insulin sensitivity in peripheral tissues. It does not stimulate insulin secretion from the pancreas and therefore carries a lower risk of hypoglycemia compared with sulfonylureas.